Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2002

View Archived Issues

ImClone Systems and Bristol-Myers Squibb revise Erbitux agreement

Onyx and Proacta to collaborate on therapeutic virus research and development

Fujirebio Diagnostics acquires rights to develop cancer diagnostics using Survivin gene

AtheroGenics begins phase I trial of transplant rejection drug AGI-1096

Encouraging results of DCVax-Prostate in late-stage prostate cancer

Ionix and Xenome collaborate on analgesic drug discovery

Institut Pasteur to evaluate Novirio compounds for hemorrhagic fever viruses

AltaRex initiates OvaRex pharmacokinetic study

Actonel found to be equieffective in weekly or daily doses in postmenopausal women

Lundbeck drops potential anxiolytic from pipeline

Cipralex/Lexapro heads for major launches by mid-2002

Allopurinol exerts immunomodulating effects in experimental autoimmune uveitis

Once-daily ravuconazole effective and safe in Rx of onychomycosis

Safety of repinotan demonstrated in subjects with severe traumatic brain injury

European phase II pancreatic adenocarcinoma trial of investigational camptothecin derivative reports

Clinical results for efalizumab in plaque psoriasis constitute a highlight of the AAD meeting

The Medicines Company acquires rights to clevidipine

Researchers at Zentaris describe novel series of antitumor agents

CPMP recommends expansion of desloratadine indication to indoor and outdoor allergies

Additional trial requested for sNDA of Thalomid in early stage multiple myeloma

FDA finds Soltara not approvable

Thirty-six new products reach their first markets in 2001

Chugai identifies coumarin derivatives useful as TNF-alpha inhibitors

Nucleoside analogues and their use as antiviral agents reported

Compounds that inhibit cholesterol biosynthesis and their uses claimed by Boehringer Ingelheim

Lundbeck patents novel inhibitors of glycine transporters